Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Key Takeaway: Genmab has announced findings regarding Epcoritamab's effectiveness in elderly patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). The article highlights monotherapy and combination regimens showing high response rates. However, specific details about the study's results and implications are not provided.